Electra Therapeutics Q3 net loss widens to $23.9 million
ETRA•Electra Therapeutics reported a third-quarter 2026 net loss of $23.9 million and had $402.5 million in cash, cash equivalents and marketable securities at September 30, with planned operations funded into 2029.
1. Quarterly results and cash
Electra Therapeutics reported a third-quarter 2026 net loss of $23.9 million. Research and development expenses were $17.3 million and general and administrative expenses were $7.8 million. The company had $402.5 million in cash, cash equivalents and marketable securities at September 30, with planned operations funded into 2029.
2. Clinical program milestones
Healthy-volunteer data for ELA822 are expected in the first half of 2027, while enrollment completion for ipsoprubart’s sHLH registrational program is expected in the second half.
